Posts by Dawn Dufield, Ph.D.

Previously she had been with Pfizer and legacy companies for over 20 years working in the quantitative LC-MS/MS field. She was one of the early pioneers of using immunoaffinity combined with LC-MS/MS to offer additional selectivity which is now commonly referred to as Hybrid LCMS. She has numerous publications and presentations in her field and recently contributed to a white paper on recommendations for validation of LCMS based bioanalytical methods for protein biotherapeutics.

PATTERN_BLUE_1320x780 Blogs
Read article Is Hybrid LC-MS/MS Emerging as an Equal Partner to LBA for the Analysis of Biotherapeutics?
Is Hybrid LC-MS/MS Emerging as an Equal Partner to LBA for the Analysis of Biotherapeutics?

There has been an increasing focus on large molecule therapeutics and pharmaceutical companies have increasingly aligned their development pipelines in that direction. This has resulted in more biological therapeutics coming to market.  Last year,…

PATTERN_AMBER_1320x780_3 Blogs
Read article The Advantage of Disease-Specific Custom Panel Biomarkers by LC-MS/MS at KCAS
The Advantage of Disease-Specific Custom Panel Biomarkers by LC-MS/MS at KCAS

Biomarkers are key drivers in the drug development process.  Frequently, developing a panel of biomarkers to test a particular mechanism or hypothesis is critical to the success of a drug.  At KCAS, we develop assays for custom panels or individual biomarkers based on client needs and can also assist with…

PATTERN_BLUE_1320x780_2 Blogs
Read article Q and A: Immunoaffinity and Hybrid LC-MS/MS
Q and A: Immunoaffinity and Hybrid LC-MS/MS

Biomarker are key drivers in the drug development process.  Frequently, developing a panel of biomarkers to test a particular mechanism or hypothesis is critical to the success of a drug.  At KCAS, we develop assays for custom panels or individual biomarkers based on client needs and can also assist with…